AtriCure Inc.

66.10-1.49-2.20%Vol 54.78K1Y Perf 78.84%
Apr 16th, 2021 11:12 DELAYED
BID65.97 ASK66.11
Open67.40 Previous Close67.59
Pre-Market- After-Market-
 - -%  - -
Target Price
67.00 
Analyst Rating
Strong Buy 1.33
Potential %
0.98 
Finscreener Ranking
★★★★+     56.26
Insiders Trans % 3/6/12 mo.
-100/-91/-94 
Value Ranking
★★★★     56.14
Insiders Value % 3/6/12 mo.
-100/-96/-97 
Growth Ranking
★★+     48.87
Insiders Shares Cnt. % 3/6/12 mo.
-100/-94/-96 
Income Ranking
 —    -
Market Cap3.02B 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
93.61 
Earnings Date
27th Apr 2021

Today's Price Range

66.1068.29

52W Range

34.0468.29

5 Year PE Ratio Range

-35.80-23.70

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
2.56%
1 Month
2.25%
3 Months
19.42%
6 Months
66.11%
1 Year
78.84%
3 Years
220.48%
5 Years
317.22%
10 Years
402.53%

TickerPriceChg.Chg.%
ATRC66.10-1.4900-2.20
AAPL133.99-0.5100-0.38
GOOG2 295.75-0.9100-0.04
MSFT259.580.08000.03
XOM57.010.03000.05
WFC43.070.83001.96
JNJ161.090.70000.44
FB306.19-1.6300-0.53
GE13.46-0.0900-0.66
JPM153.281.11000.73
Financial StrengthValueIndustryS&P 500US Markets
5.40
6.20
0.14
0.18
-8.80
Leverage Ratio 1.70
ProfitabilityValueIndustryS&P 500US Markets
72.30
-20.90
-16.30
-18.90
-20.31
RevenueValueIndustryS&P 500US Markets
153.31M
3.36
5.55
10.30
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.26-0.1830.77
Q03 2020-0.33-0.1166.67
Q02 2020-0.59-0.3835.59
Q01 2020-0.38-0.365.26
Q04 2019-0.41-0.379.76
Q03 2019-0.28-0.33-17.86
Q02 2019-0.18-0.175.56
Q01 2019-0.24-0.2016.67
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.38-58.33Negative
6/2021 QR-0.31-40.91Negative
12/2021 FY-1.16-45.00Negative
12/2022 FY-0.81-58.82Negative
Next Report Date27th Apr 2021
Estimated EPS Next Report-0.38
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume54.78K
Shares Outstanding45.63M
Trades Count944
Dollar Volume37.94M
Avg. Volume372.42K
Avg. Weekly Volume268.03K
Avg. Monthly Volume324.97K
Avg. Quarterly Volume374.17K

AtriCure Inc. (NASDAQ: ATRC) stock closed at 67.59 per share at the end of the most recent trading day (a 1.95% change compared to the prior day closing price) with a volume of 310.99K shares and market capitalization of 3.02B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 730 people. AtriCure Inc. CEO is Michael H. Carrel.

The one-year performance of AtriCure Inc. stock is 78.84%, while year-to-date (YTD) performance is 21.41%. ATRC stock has a five-year performance of 317.22%. Its 52-week range is between 34.04 and 68.29, which gives ATRC stock a 52-week price range ratio of 93.61%

AtriCure Inc. currently has a PE ratio of -57.40, a price-to-book (PB) ratio of 7.35, a price-to-sale (PS) ratio of 19.61, a price to cashflow ratio of 255.30, a PEG ratio of 2.32, a ROA of -7.29%, a ROC of -10.42% and a ROE of -14.13%. The company’s profit margin is -20.31%, its EBITDA margin is -16.30%, and its revenue ttm is $153.31 Million , which makes it $3.36 revenue per share.

Of the last four earnings reports from AtriCure Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.38 for the next earnings report. AtriCure Inc.’s next earnings report date is 27th Apr 2021.

The consensus rating of Wall Street analysts for AtriCure Inc. is Strong Buy (1.33), with a target price of $67, which is +0.98% compared to the current price. The earnings rating for AtriCure Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AtriCure Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AtriCure Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 10.25, ATR14 : 2.76, CCI20 : 125.93, Chaikin Money Flow : 0.19, MACD : 1.39, Money Flow Index : 65.54, ROC : 8.56, RSI : 55.73, STOCH (14,3) : 99.24, STOCH RSI : 1.00, UO : 56.82, Williams %R : -0.76), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AtriCure Inc. in the last 12-months were: Douglas J. Seith (Sold 62 719 shares of value $2 996 374 ), Justin J. Noznesky (Option Excercise at a value of $549 000), Justin J. Noznesky (Sold 66 794 shares of value $3 307 426 ), Mark A. Collar (Option Excercise at a value of $103 000), Mark A. Collar (Sold 14 000 shares of value $643 014 ), Mark R. Lanning (Option Excercise at a value of $51 500), Michael H. Carrel (Option Excercise at a value of $7 281 250), Michael H. Carrel (Sold 400 000 shares of value $22 475 129 ), Regina Groves (Sold 6 313 shares of value $264 073 ), Salvatore Privitera (Sold 14 500 shares of value $729 555 ), Scott W. Drake (Buy at a value of $500 669)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (77.78 %)
7 (77.78 %)
5 (71.43 %)
Moderate Buy
1 (11.11 %)
1 (11.11 %)
1 (14.29 %)
Hold
1 (11.11 %)
1 (11.11 %)
1 (14.29 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.33
Strong Buy
1.33
Strong Buy
1.43

AtriCure Inc.

AtriCure Inc an atrial fibrillation solutions company that provides products, professional education, and support for clinical science to reduce the economic and social burden of atrial fibrillation. Its products line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offer a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.

CEO: Michael H. Carrel

Telephone: +1 513 755-4100

Address: 7555 Innovation Way, Mason 45040, OH, US

Number of employees: 730

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

57%43%

Bearish Bullish

52%48%

Bearish Bullish

61%39%

News

Stocktwits